BIOREGULATORY APPROACH TO COMBINATION THERAPY FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
- Authors: Komleva N.1, Maryanovsky A.2, Danilov A.1, Zaikina I.1
-
Affiliations:
- Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- N.I. Pirogov Russian National Research Medical University
- Issue: Vol 27, No 12 (2016)
- Pages: 42-44
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116791
- ID: 116791
Cite item
Open Access
Access granted
Abstract
The paper gives the results of an open-label longitudinal randomized study, which suggest that is expedient to incorporate the antihomotoxic agents Spascupreel and Mucosa compositum into combination therapy for patients with gastroesophageal reflux disease; the drugs regress the symptoms of the disease, increase the period of remission, and improve the results of endoscopic studies and the indicators of quality of life.
Full Text
About the authors
N. Komleva
Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: NEKomleva@yandex.ru
MD; Professor Moscow
A. Maryanovsky
N.I. Pirogov Russian National Research Medical UniversityMD Moscow
A. Danilov
Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human WelfareAssociate Professor Candidate of Medical Sciences Moscow
I. Zaikina
Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human WelfareCandidate of Medical Sciences Moscow
References
- Bashashati M., Hejazi R., Andrews C. et al. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? // Can. J. Gastroenterol. Hepatol. -2014; 28 (6): 335-41.
- Bruley des Varannes S., Cestari R., Usova L. et al. Classification of adults suffering from typical gastroesophageal reflux disease symptoms: contribution of latent class analysis in a European observational study // BMC Gastroenterol. -2014; 14: 112.
- El-Serag H., Sweet S., Winchester C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review // Gut. - 2014; 63 (6): 871-80.
- Mason J., Hungin A. Review article: gastro-oesophageal reflux disease -the health economic implications // Aliment. Pharmacol. Ther. - 2005; 22 (1): 20-31.
- Tack J., Becher A., Mulligan C. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life // Aliment. Pharmacol. Ther. - 2012; 35 (11): 1257-66.
- Nwokediuko S. Current trends in the management of gastroesophageal reflux disease: a review // ISRN Gastroenterol. - 2012; ID391631.
- Boeckxstaens G., El-Serag H., Smout A. et al. Symptomatic reflux disease: the present, the past and the future // Gut. - 2014; 63 (7): 1185-93.
- Subramanian C., Triadafilopoulos G. Refractory gastroesophageal reflux disease // Gastroenterol. Rep. - 2015; 3 (1): 41-53.
- Bueno L., Lafforgue G., Beaufrand C. et al. Colonic and anorectal disorders targeting the IBS pathophysiology in stressed rats using a multicomponent HE-400 // J. Gastroenterol. Hepatol. - 2013; 28 (suppl. 3): 347-8.
- Комлева Н.Е., Спирин В.Ф., Заикина И.В. Изучение эффективности антигомотоксической терапии ГЭРБ // Международный журнал прикладных и фундаментальных исследований. - 2015; 8-1: 52-4.
- Lundell L., Dent J., Bennett J. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angelesclassification // Gut. - 1999; 45 (2): 172-80.
- Ware J. SF-36 Health Survey Update // Spine. - 2000; 25: 3130-9.
- Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине / СПб: Нева, 2002; 320.
Supplementary files
